Clinical outcomes and germline implications of primary KIT exon 13 and 17 mutations in gastrointestinal stromal tumors
Gastric Cancer · 2026-11 · 29 (6) · 1258-1267
DOI: 10.1007/s10120-026-01810-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastric Cancer, online erschienen am 21.10.2026. Verfasst von Jaewon Hyung und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Kor…. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Proto-Oncogene Proteins c-kit, Imatinib Mesylate, Germ-Line Mutation. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
Primary KIT exon 13 and 17 mutations are rare in gastrointestinal stromal tumors (GISTs), and data on their response to imatinib are limited. We evaluated the clinical characteristics and outcomes.
Methods
We analyzed 1524 patients with metastatic or recurrent GIST treated with first-line imatinib between 2005 and 2024 at Asan Medical Center, Seoul, Korea. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared between the primary KIT exon 13 or 17 and exon 11 group. ORR was assessed only in patients with measurable lesions, whereas PFS and OS were analyzed in all patients. Germline sequencing was performed when available.
Results
Twenty-seven patients (1.8%) harbored primary KIT exon 13 (n = 20) or 17 (n = 7) mutations. ORR to imatinib tended to be lower for exon 13 (6/13, 46.2%) and exon 17 (1/3, 33.3%) than exon 11 (558/799, 69.8%; p = 0.144). Median PFS was 17.8, 18.6, and 57.1 months for exon 13, 17, and 11, respectively ( p < 0.001); 24-month PFS rates were 37.9%, 33.3%, and 74.2%, respectively. The 24-month OS rates were 92.3%, 71.4%, and 94.8%. Of 19 patients tested, two harbored germline exon 13 mutations, including one with a family history.
Conclusions
Imatinib showed modest clinical activity in GISTs harboring primary KIT exon 13 or 17 mutations and remains a reasonable first-line option in the absence of established alternatives, although outcomes were less favorable than in exon 11. Family history and germline sequencing should be considered in young patients with exon 13 mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. miniryu@amc.seoul.kr.
Zitieren
APA
Hyung, J., Kim, H. D., Jang, E., Ma, J., Park, Y. S., & Ryu, M. H. (2026). Clinical outcomes and germline implications of primary KIT exon 13 and 17 mutations in gastrointestinal stromal tumors. Gastric Cancer, 29(6), 1258-1267. https://doi.org/10.1007/s10120-026-01810-2
Vancouver
Hyung J, Kim HD, Jang E, Ma J, Park YS, Ryu MH. Clinical outcomes and germline implications of primary KIT exon 13 and 17 mutations in gastrointestinal stromal tumors. Gastric Cancer. 2026;29(6):1258-1267. doi:10.1007/s10120-026-01810-2
BibTeX
@article{Hyung2026,
author = {Hyung, Jaewon and Kim, Hyung-Don and Jang, Eunji and Ma, Jungeun and Park, Young Soo and Ryu, Min-Hee},
title = {Clinical outcomes and germline implications of primary KIT exon 13 and 17 mutations in gastrointestinal stromal tumors},
journal = {Gastric Cancer},
year = {2026},
volume = {29},
number = {6},
pages = {1258--1267},
doi = {10.1007/s10120-026-01810-2}
}
EUVIMED